A Phase I/II proof-of-concept clinical trial to investigate topical product candidate SNA-125 in the treatment of atopic dermatitis
Phase of Trial: Phase I/II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs SNA 125 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Sienna Biopharmaceuticals
- 12 Mar 2018 According to Sienna Biopharmaceuticals media release, the first patient has been dosed in this trial.
- 12 Mar 2018 According to Sienna Biopharmaceuticals media release, the company expects to report the results in the fourth quarter of 2018.
- 12 Mar 2018 Status changed from planning to recruiting, according to Sienna Biopharmaceuticals media release.